Why NORML Says Rescheduling Cannabis Isn't Enough

August 16, 2026

Photo by stevepb via Pixabay.

Introduction

The executive order landed on December 18, 2025, and for a moment it looked like the biggest shift in federal cannabis policy in half a century. President Trump directed the Attorney General to expedite moving marijuana from Schedule I to Schedule III, and the industry exhaled. But executive orders don't reschedule drugs, they just order agencies to move faster, and what has followed is a slow, grinding process full of procedural fights and narrowing definitions. Acting Attorney General Todd Blanche issued his order in April 2026, but it only covered FDA approved products and state licensed medical cannabis, leaving recreational markets and unlicensed medical patients exactly where they were before. The DEA held a hearing this summer, but before anyone could argue the merits, groups like NORML had to fight just to get a seat at the table. What was sold as a straightforward regulatory fix has turned into something messier, a hybrid scheduling category Congress never designed, an administrative hearing that excludes the most prominent reform organization, and a legislative alternative sitting in the Senate with no clear path forward. Understanding where cannabis policy actually stands requires walking through the timeline, the legal maneuvers, and the gap between what rescheduling promises and what it actually delivers.

How We Got Here: From Executive Order to DEA Hearing

Photo by Margaret Giatras via Unsplash.

The timeline matters here because the politics have shifted so many times that it's easy to lose track of what's actually in effect versus what's still pending. Start with December 18, 2025, when President Trump signed Executive Order 14370, directing the Attorney General to expedite moving cannabis off Schedule I and onto Schedule III. That order didn't reschedule anything by itself -- executive orders don't work that way for controlled substances -- but it put a deadline pressure on the Department of Justice that hadn't existed under the previous multi-year rulemaking drag.

Four months later, Acting Attorney General Todd Blanche acted on that directive. On April 23, 2026, Blanche issued an order that immediately placed two specific categories into Schedule III: FDA-approved marijuana products, and state-licensed medical marijuana products. That's a narrower move than it might sound. It doesn't touch recreational cannabis, and it doesn't cover medical marijuana obtained outside a licensed state program -- someone in a state with no medical program, or buying from an unlicensed source, is still dealing with a Schedule I substance in the eyes of federal law, the same legal category as heroin. That distinction matters for anyone trying to figure out where they actually stand: a state-licensed medical patient in, say, Ohio or Pennsylvania is in a different legal position than a recreational consumer in Colorado, even though both states have fully legal markets. As always, the specifics vary by state, and confirming your own state's licensing status before assuming any federal protection applies is worth the ten minutes it takes.

Blanche's order also did something procedural but consequential: it set up an expedited administrative hearing process to weigh whether cannabis should move further, potentially out of Schedule III entirely or into a different framework altogether. That hearing process kicked off June 29, 2026, run through the DEA's administrative law framework, with testimony and evidence from industry groups, medical researchers, and advocacy organizations including NORML. The hearing concluded July 15, 2026, but that's not the end of the story -- post-hearing briefs and closing arguments are still due before the administrative law judge issues any recommendation, and that recommendation then has to work its way through the DEA and DOJ before anything becomes final. In other words, the hearing is over, but the paperwork that actually determines the outcome is still being written.

NORML's Fight to Even Get a Seat at the Table

Photo by Mikhail Nilov via Pexels.

Before NORML could argue the merits of rescheduling, it first had to fight for the right to argue at all. The organization filed to formally participate in the DEA's rescheduling hearing as an interested party, and the DEA turned it down. That denial might sound like a procedural footnote, but it's the kind of gatekeeping decision that determines whose voice actually gets heard in a process that will shape cannabis policy for decades.

NORML didn't let the rejection stand. On June 19, 2026, the organization sent a letter directly to the DEA Administrator asking for reconsideration. As a backup, the letter asked that the question be certified for interlocutory appeal to the presiding officer overseeing the hearing -- essentially asking a higher authority within the process to weigh in before the case moves any further, rather than waiting until the very end to challenge the exclusion.

The legal argument NORML is leaning on is fairly straightforward under administrative law: to participate as an interested person, a party generally has to show it's adversely affected by the outcome the agency is proposing. NORML's position is that it clears that bar easily. If cannabis lands in Schedule III instead of coming off the schedule entirely, that outcome directly affects an organization whose entire mission for over five decades has been built around ending federal prohibition and treating cannabis the way alcohol or tobacco is treated -- not folding it into the same regulatory framework as anabolic steroids and ketamine.

There's a genuine irony baked into this fight, and NORML isn't shy about pointing it out. The organization broadly supports moving cannabis out of Schedule I -- that's been the goal for as long as NORML has existed. But it objects specifically to Schedule III as the landing spot, precisely because Schedule III still leaves cannabis under a federal control regime that Congress never designed for a substance sold in state-licensed storefronts to millions of adult consumers. Supporting the direction of travel while objecting to the destination is a nuanced position, and nuance doesn't always translate cleanly into standing for a formal hearing.

That's really the story underneath this whole procedural skirmish: a rescheduling process that was pitched as a straightforward regulatory fix has turned into a slow-moving legal battle over who even gets a microphone.

Why Schedule III Isn't the Finish Line, According to NORML

Photo by jarmoluk via Pixabay.

Rescheduling to Schedule III still means cannabis remains a controlled substance under federal law, alongside things like ketamine and anabolic steroids. NORML's argument is blunt: that's not the same as regulating cannabis the way we regulate alcohol or tobacco, which sit entirely outside the Controlled Substances Act. Under Schedule III, simple possession without a prescription is still a federal crime on paper. Someone buying legal weed at a state-licensed dispensary in Colorado or Michigan is, technically, still committing a federal offense every time they walk out the door with it. Moving cannabis down two schedules doesn't erase that exposure -- it just softens the penalty structure while leaving the underlying criminality intact.

There's also a messier problem baked into the April 2026 order that critics -- NORML included -- have been vocal about: it doesn't cleanly place cannabis into the existing Schedule III box. Ordinary Schedule III drugs don't carry production quotas, import-export permit requirements, or the kind of enhanced DEA registration hurdles that have historically applied to Schedule I and II substances. Cannabis, under this order, keeps all of that. What you end up with is a hybrid category Congress never wrote into the statute -- cannabis nominally in Schedule III but functionally still shackled to Schedule I/II-style controls. That's an administrative patch job, not a coherent legal framework, and it leaves DEA with enormous discretion to keep treating cannabis like a more dangerous substance than its new schedule number suggests.

The research angle gets misunderstood a lot. People assume Schedule I status is the sole reason clinical cannabis research has crawled for decades. In reality, a lot of the worst bottlenecks -- restrictions on cultivar sourcing, requirements tied specifically to marijuana research registration, limits on who can grow research-grade cannabis -- are written into marijuana-specific statutory language, not the general Schedule I rules that apply to every controlled substance. Rescheduling doesn't touch those provisions. Congress would need to go back and amend those marijuana-specific sections directly, something the April 2026 order simply can't do by itself, no matter how the substance is classified.

Perhaps the biggest gap: state-legal recreational markets get nothing from this. The order is narrowly aimed at FDA-approved cannabis products and state medical programs -- it doesn't extend any protection, clarity, or banking relief to the adult-use markets operating in more than twenty states. Those businesses still can't access normal banking, still can't deduct standard business expenses under IRS code Section 280E in the way other industries can, and still operate in a legal gray zone the rescheduling order does nothing to resolve. NORML's read is that Schedule III looks like progress on paper but leaves the actual structural problems facing the legal cannabis industry almost entirely untouched -- a bureaucratic reshuffling rather than the legislative fix cannabis policy has needed for decades.

The Legislative Alternative: The Cannabis Administration and Opportunity Act

Photo by MotionStudios via Pixabay.

While the DEA's rescheduling review has dragged on, Capitol Hill produced its own answer to the same question in July 2026: descheduling, not rescheduling. Senators Cory Booker (D-NJ), Chuck Schumer (D-NY), and Ron Wyden (D-OR) reintroduced the Cannabis Administration and Opportunity Act, picking up 13 additional Democratic cosponsors in the process. NORML's response was immediate and enthusiastic, framing CAOA as the version of reform that actually matches the scale of the problem rather than one that just relabels it.

The distinction matters more than it might sound. Moving cannabis to Schedule III, the outcome the DEA's own administrative process has been inching toward, would still leave it as a federally controlled substance subject to registration requirements, production quotas, and a patchwork of restrictions that don't apply to alcohol or tobacco. CAOA takes a different approach entirely: it removes marijuana from the Controlled Substances Act altogether. No schedule, no federal criminal status tied to simple possession or sale, and a regulatory framework that shifts oversight to agencies like the Treasury Department, the FDA, and the Alcohol and Tobacco Tax and Trade Bureau — the same kind of setup that already governs beer, wine, and spirits.

That structural difference is why NORML treats CAOA as something closer to a blueprint than just another bill in the hopper. The legislation also carries provisions on expungement of past federal cannabis convictions, tax policy for state-licensed operators still locked out of normal business deductions under IRS code section 280E, and funding mechanisms aimed at communities hit hardest by decades of enforcement. None of that is achievable through an agency rulemaking, no matter how the DEA ultimately rules on scheduling.

Realistically, CAOA's odds of passing this Congress are slim. Similar versions of the bill have circulated in the Senate since 2021 without reaching a floor vote, and the current chamber math doesn't favor swift action on a Democratic-sponsored cannabis bill. That's the tension NORML keeps pointing to: an administrative process that might land on a compromise (Schedule III) running alongside a legislative process aimed at ending prohibition outright, with no guarantee either one moves before the other stalls out. For now, CAOA functions less as a near-term legislative prospect and more as a marker of what NORML and its allies consider the actual finish line, with rescheduling treated as, at best, a stopover along the way.

Conclusion

So where does that leave the cannabis industry, the patients, and the millions of consumers in state legal markets? In a holding pattern that feels increasingly familiar. The DEA hearing concluded in July, but the administrative law judge still has to issue a recommendation, and that recommendation then has to survive review at both the DEA and DOJ before anything becomes final. That process could stretch well into next year, and even if Schedule III eventually takes effect, it won't touch recreational markets, won't fix the banking problem, won't lift Section 280E, and won't change the fact that simple possession remains a federal crime on paper. NORML's position is that Schedule III is a bureaucratic reshuffling, not the structural reform the country needs, and their support for the Cannabis Administration and Opportunity Act reflects that view. But CAOA has been introduced multiple times without reaching a floor vote, and the current Congress shows little appetite for moving it. The rescheduling process, whatever its flaws, is at least moving, while legislation sits still. That gap, between administrative action and legislative reform, is the real story of cannabis policy in 2026. The direction of travel has shifted, but the destination remains unclear, and the people who built businesses and lives around state legal markets are still waiting for Washington to catch up with what voters have already decided.